<DOC>
	<DOC>NCT00670267</DOC>
	<brief_summary>The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness.</brief_summary>
	<brief_title>Oral Nadolol for the Treatment of Adults With Mild Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Nadolol</mesh_term>
	<criteria>Prebronchodilator FEV1 80% or greater than the predicted value. PC20 FEV1 ≤4 mg/ml on methacholine challenge test. Blood Pressure ≥ 100/65mm Hg. Pulse rate ≥ 60 beats/min. No significant health issues. Nonsmoker or Xsmoker &lt; 10 pack/year. History of upper/lower respiratory tract infection or asthma exacerbation within 6 weeks of first baseline visit. Currently diagnosed with chronic obstructive pulmonary disease (COPD). Used any oral or inhaled corticosteroids within 4 weeks of the first baseline visit.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>hyperresponsiveness</keyword>
</DOC>